Bokf Na Has $18.79 Million Position in Abbott Laboratories $ABT

Bokf Na boosted its stake in Abbott Laboratories (NYSE:ABT) by 3.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 140,308 shares of the healthcare product maker’s stock after purchasing an additional 4,822 shares during the quarter. Bokf Na’s holdings in Abbott Laboratories were worth $18,793,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after acquiring an additional 2,977,715 shares during the period. State Street Corp raised its position in shares of Abbott Laboratories by 0.9% during the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after purchasing an additional 689,517 shares during the period. Capital International Investors lifted its holdings in shares of Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares in the last quarter. Geode Capital Management LLC grew its position in Abbott Laboratories by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock valued at $5,184,589,000 after purchasing an additional 1,390,554 shares during the period. Finally, Norges Bank bought a new stake in Abbott Laboratories during the 2nd quarter valued at $3,026,180,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, EVP Elizabeth C. Cushman sold 263 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $30,397.54. Following the transaction, the executive vice president directly owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. The trade was a 0.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the transaction, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $110.20 on Thursday. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.06. The company’s 50 day moving average price is $115.25 and its two-hundred day moving average price is $124.19. The stock has a market cap of $191.50 billion, a P/E ratio of 29.62, a P/E/G ratio of 1.76 and a beta of 0.74. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott launched year two of the “Abbott Dream Team” program with Real Madrid to engage U.S. youth and raise brand visibility for Abbott’s consumer/diagnostics businesses — a marketing move that can boost long‑term consumer awareness. Abbott and Real Madrid launch nationwide effort to build the next ‘Abbott Dream Team’
• Positive Sentiment: Coverage highlighting Abbott as a durable dividend name / “safer” dividend aristocrat supports income‑oriented investor demand and may underpin share support despite near‑term volatility. Hope for the Best and Plan for the Worst: The 5 Safest Dividend Aristocrats
• Positive Sentiment: Analyst writeups from Zacks highlight Abbott as both a long‑term value and growth stock based on style scores — these pieces can attract buy‑and‑hold investors and lift sentiment over time. Why Abbott (ABT) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Recent short‑term price coverage noted a bounce to roughly $112.65 on the last close, reflecting intra‑week volatility; this is informational but not a catalyst on its own. Abbott (ABT) Rises Higher Than Market: Key Facts
• Negative Sentiment: Citigroup trimmed its price target from $140 to $136 while maintaining a “buy” rating — a downgrade in upside potential that can blunt investor enthusiasm and weigh on the share price. Citigroup trims ABT price target (Benzinga)
• Negative Sentiment: Valuation and performance writeups point to a mixed share performance (YTD and 1‑year declines) and debate whether current pricing fully discounts Abbott’s growth risks — such narratives can trigger additional selling from momentum or quant strategies. Is Abbott Laboratories (ABT) Pricing Reflect Its Mixed Share Performance And Growth Prospects?

Analyst Ratings Changes

A number of research firms have weighed in on ABT. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Raymond James Financial lowered their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group dropped their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Piper Sandler decreased their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Finally, Barclays lowered their price objective on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.